---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-031202"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2023-07-03T23:59:59+00:00"
generated_at: "2026-06-13T13:34:52.831870+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MannKind: fire at contract manufacturer delays MNKD-101 clinical supply by 3-6 months

## Summary
- Fire at contract manufacturer's German facility producing clofazimine inhalation solution (MNKD-101).
- Production of clinical supplies delayed by 3-6 months.
- Planned Phase 2/3 clinical study initiation for later 2023 may be impacted.
- Company evaluating mitigation strategies; will update timing projections later.

## SEC filing metadata
- accession: 0000950170-23-031202
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2023-07-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000095017023031202/0000950170-23-031202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000095017023031202/mnkd-20230626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-031202
- JSON: https://secwatch.observer/filing/0000950170-23-031202.json
- Plain text: https://secwatch.observer/filing/0000950170-23-031202.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.